Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 4/20 | 0.35 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069682 | 1.00 | TYMP (0.42) | TYMPTMIGD3TYMSPOLBDNMT1 | |
| SCHEMBL8169445 | 0.88 | TYMP (0.39) | TYMPTMIGD3TYMSPOLBDNMT1 | |
| SCHEMBL261967 | 0.88 | TYMP (0.46) | TYMPTMIGD3TYMSPOLBADORA3 | |
| SCHEMBL21828786 | 0.88 | TYMP (0.46) | TYMPTMIGD3TYMSPOLBADORA3 | |
| SCHEMBL22984016 | 0.88 | TYMP (0.46) | TYMPTMIGD3TYMSPOLBADORA3 | |
| SCHEMBL3510678 | 0.85 | TYMP (0.43) | TYMPTMIGD3TYMSPOLBADORA3 | |
| SCHEMBL3510681 | 0.85 | TYMP (0.43) | TYMPTMIGD3TYMSPOLBADORA3 | |
| SCHEMBL5358852 | 0.82 | POLB (0.56) | TYMPTYMSPOLBADORA3 | |
| SCHEMBL5925303 | 0.82 | POLB (0.56) | TYMPTYMSPOLBADORA3 | |
| SCHEMBL21504687 | 0.81 | POLB (0.40) | TYMPTMIGD3POLBADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092046-A1 | Guanidinium functionalized oligomers and methods | MANOHARAN MUTHIAH (US) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092046-A1 | Guanidinium functionalized oligomers and methods | RNMT, RNGTT, ADAR | TYMP 571/4885TMIGD3 2619/4885TYMS 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.